Villela L, Herrera-Gamboa J, Fajardo-Ramírez O, Hernández-Hernández JA

Language: Spanish
References: 11
Page: 148-151
PDF size: 347.75 Kb.

Text Extraction

No abstract.

REFERENCES

1. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002;513:124-128.

2. Poppe B, Dastugue N, Vandesompele J, et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006;45:349-356.

3. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.

4. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014;157:369-381.

5. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-223.

6. Seda V, Mraz M. B cell receptor (BCR) signaling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 2014 Aug 1. doi: 10.1111/ejh.12427.

7. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-2294.

8. [No authors listed]. Recurrent BTK and PLCG2 mutations confer ibrutinib resistance. Cancer Discov 2014;4:866. doi: 10.1158/2159-8290.CD-RW2014-128. Epub 2014 Jun 12.

9. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-2315.

10. Kim G, McKee AE, Ning YM, et al. FDA Approval Summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAF V600E mutation. Clin Cancer Res 2014 Aug 5. pii: clincanres.0776.2014.

11. Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol 2014;15:187-209.